Abstract P2-12-06: Ultra-low dose vaginal estriol and Lactobacillus acidophilus (Gynoflor®) in early breast cancer survivors on aromatase inhibitors: Pharmacokinetic, efficacy and safety results from a phase I study.
Patrick Neven(KU Leuven), Stefan Buchholz(University Hospital Regensburg), Olaf Ortmann(University of Regensburg), Gilbert Donders(Institut Scientifique de Santé Publique), Anneleen Lintermans(Universitair Ziekenhuis Leuven), M Mögele(University Hospital Regensburg), Gert Bellen(Flemish Community)
Cited by 2
Related Papers
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy
|BJOG An International Journal of Obstetrics & Gynaecology|2009|436